Amarin
Amarin announces intention to list on AIM and IEX markets
Published in Mental Health Law Weekly, July 15th, 2006
Amarin will retain its primary listing on NASDAQ and is not seeking any additional capital as part of the listing process. Amarin is already well funded with $33 million in cash as at March 31, 2006. Admission to AIM and IEX is expected to occur in mid July.
Admission to AIM and IEX will enhance Amarin's profile amongst commercial and financial audiences in Europe. It will also enable European investors to trade Amarin shares on an open...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Law Weekly
More Articles from Mental Health Law Weekly
- Baylor College of Medicine, U.S.
Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice - BioMS Medical
European Journal of Neurology publishes MBP8298 Phase II and long-term follow-up data - University of Liege, Belgium
Junior physicians taught communication and stress management skills to deal with cancer patients - i3 Research
Antidepressant prescriptions in children decrease nearly 10% after warnings were issued - Aarhus University Hospital, Aarhus, Denmark
Preharvest CD34+ count correlates with total number of collected CD34+ cells/kg - American Medical Association
Statin use is associated with reduced risk of a common type of cataract - More from this issue of Mental Health Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
